Clinical Efficacy and Prognosis of Budesonide Nasal Spray in the Treatment of Allergic Rhinitis

  • Zhou Wang Department of Otolaryngology, Head and Neck Surgery
  • Dong Lin The Quality Control Office of Shaanxi Provincial Second Rehabilitation Hospital
Keywords: Allergic Rhinitis; Budesonide Nasal Spray; Therapeutic Efcacy; Prognosis; Loratadine

Abstract

To explore the clinical efcacy of budesonide nasal spray in the treatment of allergic rhinitis. Methods: 100 patients with allergic rhinitis who received treatment in our hospital from January 2022 to January 2023 were selected as the study subjects. Patients were ran-domly divided into two groups, a control group and an experimental group, with 50 patients in each group. Both groups of patients require treatment with loratadine. On this basis, patients in the experimental group were more likely to use budesonide nasal spray than patients in the control group. Observe the efcacy and adverse reactions of the two groups of patients. Results: The treatment efect and recurrence rate of rhinitis in the experimental group were better than those in the control group, and the treatment efect was good. The recurrence rate of pa-tients was also decreasing. There was no signifcant diference in adverse reactions between the two groups (P>0.05). Conclusion The exper-imental group of budesonide nasal spray has good efcacy and prognosis in the treatment of allergic rhinitis, with safety assurance and ideal application efect, which is worthy of clinical promotion and application.

References

[1] Liu M, Chen YY, Su L, Sun MQ. Clinical study on the treatment of acute sinusitis with nasal sinusitis oral liquid and budesonide in

experimental group [J]. Modern Medicine and Clinical, 2021 (03).

[2] Zhang LY, Chen YF. Clinical efficacy of budesonide inhalation in the treatment of acute infectious laryngitis in children in the ex_x005fperimental group [J]. North Pharmaceutical, 2022 (07).

Published
2023-12-27
Issue
Vol 12 No 4 (2023)
Section
Review Article

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.